EMA-CO chemotherapy for high-risk GTN stands for which drug combination?

• A Epirubicin, Methotrexate, Ara-C, Carboplatin, Oxaliplatin
• B Etoposide, Melphalan, Adriamycin, Cisplatin, Ondansetron
• C Etoposide, Methotrexate, Actinomycin-D, Cyclophosphamide, Oxaliplatin
• D Etoposide, Methotrexate, Actinomycin-D, Cyclophosphamide, Oncovin (vincristine) ✓

Explanation

EMA-CO stands for Etoposide, Methotrexate (with folinic acid rescue), Actinomycin-D (Courses 1&2 — EMA portion), followed by Cyclophosphamide and Oncovin/vincristine (CO portion), given in alternating weekly courses. It achieves remission in 75–90% of high-risk GTN cases (WHO score ≥7). For EMA-CO–resistant disease, EP-EMA or TP/TE regimens with cisplatin are used.

Reference: Williams Obstetrics, 26th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.